

Current as of December 17, 2025

A

acute myelogenous leukemia	B008
Acute Myeloid Leukemia	B028
ALK, ROS1 fusions	A005
ALK-driven lung cancer	B032
Alveolar Rhabdomyosarcoma	A021
angiogenesis	A023
antisense oligonucleotide	B008
Apoptosis	B022
arsenic trioxide	A025
aryl hydrocarbon receptor (AhR)	A002
ASPSCR1::TFE3	A023
ATXN1	A015
Autochthonous mouse model	A016

B

Balanced translocations	B020
Bioinformatics	A012
biorepository archived samples	A005
BRAF	B026
brain	B002
BRD4::NUTM1 fusion oncogene	B014

C

cancer-associated fibroblasts	A018
Cap-dependent translation	A026
CBFA2T3::GLIS2 fusion	B018
CBFA2T3-GLIS2	B022
CDK4/6 inhibition	B018
cell of origin	A019
cfRNA extraction	A030
CIC	A015
CIC::DUX4 sarcoma	A016
CLK Inhibition	A021

AACR Special Conference in Cancer Research:

Fusion-positive Cancers: From Discovery to Therapy

January 13-15, 2026 | Hilton Philadelphia at Penn's Landing | Philadelphia, PA

CNS, ASOs, fusion oncogenes	A006
combinatorial therapies	B030
condensates	B007
Condensates	B005
Condensates, phase separation	B006
cost effective screening	A005
CRISPR	A008
CRISPR-Cas9 screening	B028

D

DDX19A	B001
degradation	A025
degrader	A029
dermatofibrosarcoma protuberans	A018, A019
development	B002
Drug tolerance	A003

E

ecDNA	A007
EndMT	B003
Enhancer-methylation	B022
ependymoma	B002
Ependymoma	B011, B025
epigenetics	B015
Epigenome	A024
Ewing	B023
Ewing sarcoma	A027, B001, B013, B019, B020
EWS/FLI1, Chromatin Destabilization	A010
EWS::FLI1	B005
EWSR1	A004
EWSR1::FLI1	B019

F

FGFR3-TACC3	A029
fibroblasts	A018, A019
Fibrolamellar Carcinoma	B031
Fusion Burden	B027

AACR Special Conference in Cancer Research:

Fusion-positive Cancers: From Discovery to Therapy

January 13-15, 2026 | Hilton Philadelphia at Penn's Landing | Philadelphia, PA

Fusion oncogenes	A008
fusion protein	A025
Fusion signaling	A003
Fusion-oncogene	A014
Fusion-positive rhabdomyosarcoma	A009
Fusion-Positive Rhabdomyosarcoma	B016, B029
fusions	A013, B023

G

Gene fusion	A012
Gene fusions	A012
Genetically engineered mouse model	A016
Glioma	B026
Glycosylation	B026

H

H3K4 methylation	A001
High-throughput	A024

I

Immunoediting	B010
Immunotherapy	A017, B032
in vivo modeling	B021

J

There were no keywords in this range.

K

KLF15	A004
-------	------

L

Larotrectinib	A029
leukemia	A001
Liquid Biopsy	A030
lurbinectedin	B013

M

AACR Special Conference in Cancer Research:

Fusion-positive Cancers: From Discovery to Therapy

January 13-15, 2026 | Hilton Philadelphia at Penn's Landing | Philadelphia, PA

Mechanisms	A012
Melanoma	B012
MET fusion	B017
Metastasis	B027
Microenvironment	B012
miRNA, MYCN, Pax3::Foxo1	B029
miR-SPonges	B029
MLL1	A001
model	A015
Molecular mechanism	A022
Molecular Stratification	B011
mouse allografts	A014
Mouse Model	A017
mRNA splicing	B013
Multomics	B031
Myc family proteins	A009
MYC, MYCN	A009
Myoepithelial Carcinoma	A004
myogenesis	B024
 N	
Natural Killer cell	B010
NFIA::CBFA2T3	B008
NRG1	A013
NSD3	B014
NTRK	A013
NTRK gene fusion	A029
nucleosome	B019
NUT carcinoma	B014
 O	
off-target resistance	B030
oncogene fusion	A007
ovarian cancer	B017
 P	
PAX3::FOXO1	B009

AACR Special Conference in Cancer Research:

Fusion-positive Cancers: From Discovery to Therapy

January 13-15, 2026 | Hilton Philadelphia at Penn's Landing | Philadelphia, PA

PAX3-FOXO1	A026
Pediatric AML, hematopoietic ontogeny	B004
Pediatric cancer	A029
perivascular tumors	B024
Precision Radiotherapy	B011
Precision targeting	A008
PROTAC	A029
PROTACs	B009
PVT1	A007

Q

There were no keywords in this range.

R

RAB27A	A023
Radiation	B025
Reciprocal fusions	B020
Recurrence	B027
rhabdomyosarcoma	B015, B021
Rhabdomyosarcoma	A026, B010
Rhabdomyosarcoma, iPSCs, pediatric cancer	A020
RTK fusion, EML4-ALK	B007

S

sarcoma	B023
Sarcoma	A012, B003
scATAC-seq	A024
skeletal muscle differentiation	A014
SOX8 Mis-splicing	A021
spatial profiling	B017
SRF fusion	B024
STING agonists	B032
Structural Biology	B005
SWI/SNF chromatin remodeling	B018
Synovial Sarcoma	A017
synthetic biology	B007
Synthetic Epigenetics	B016

AACR Special Conference in Cancer Research:

Fusion-positive Cancers: From Discovery to Therapy

January 13-15, 2026 | Hilton Philadelphia at Penn's Landing | Philadelphia, PA

T

Targeted combination therapy	A027
Targeted therapeutics	A022
Targeted therapies	A003
TF/nucleosome interactions	B016
TFE3 fusions	A002
TFE3-tRCC	A022
Therapeutic Targeting	A010
TKIs	B030
Transcription	B001, B025
transcription factor	B015, B021
translocation renal cell carcinoma (tRCC)	A002

U

There were no keywords in this range.

V

There were no keywords in this range.

W

Webpage	B031
---------	------

X

XPO1 inhibition	A027
-----------------	------

Y

YAP1-TFE3	B003
-----------	------

Z

There were no keywords in this range.

AACR Special Conference in Cancer Research:

Fusion-positive Cancers: From Discovery to Therapy

January 13-15, 2026 | Hilton Philadelphia at Penn's Landing | Philadelphia, PA